| scholarly article | Q13442814 |
| P50 | author | Hans-Jürgen Wester | Q128303541 |
| Jörg-Christian Tonn | Q47460826 | ||
| Markus Holtmannspötter | Q47460836 | ||
| Gabriele Pöpperl | Q47460838 | ||
| Markus Schwaiger | Q57016855 | ||
| P2093 | author name string | Horst Kessler | |
| Hans A Kretzschmar | |||
| Oliver Schnell | |||
| Roland H Goldbrunner | |||
| Roland Haubner | |||
| Bjarne Krebs | |||
| Ambros J Beer | |||
| Isabelle Miederer | |||
| Claudia Goetz | |||
| Janette Carlsen | |||
| P2860 | cites work | Reproducibility of metabolic measurements in malignant tumors using FDG PET | Q73192444 |
| Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival | Q77162290 | ||
| Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas | Q80778839 | ||
| Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme | Q81615619 | ||
| Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD | Q24805375 | ||
| N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists | Q30580638 | ||
| Intraoperative MR-guided neurosurgery | Q33313903 | ||
| Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. | Q33375093 | ||
| The WHO classification of tumors of the nervous system | Q33845646 | ||
| Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers | Q34343207 | ||
| Chemoradiotherapy in malignant glioma: standard of care and future directions | Q34683223 | ||
| Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis | Q35056623 | ||
| Positron emission tomography as an imaging biomarker | Q36531392 | ||
| Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting | Q36570185 | ||
| Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism | Q36611736 | ||
| Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature | Q41822458 | ||
| Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor | Q42813159 | ||
| Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography | Q43561095 | ||
| Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma | Q43573142 | ||
| Genetic pathways to glioblastoma: a population-based study | Q44673208 | ||
| [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates | Q44735126 | ||
| Quantification of [18F]diprenorphine kinetics in the human brain with compartmental and non-compartmental modeling approaches | Q44994198 | ||
| Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients | Q46639250 | ||
| Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. | Q46852304 | ||
| [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck | Q46897615 | ||
| Chemotherapy for low-grade gliomas: emerging consensus on its benefits. | Q48161385 | ||
| Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. | Q53530857 | ||
| [Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination] | Q53671242 | ||
| Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. | Q55474171 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 861-870 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography | |
| P478 | volume | 11 |
| Q34473605 | (68)Ga-PRGD2 PET/CT in the evaluation of Glioma: a prospective study |
| Q38978559 | A direct comparison of tumor angiogenesis with ⁶⁸Ga-labeled NGR and RGD peptides in HT-1080 tumor xenografts using microPET imaging. |
| Q39432642 | A new optical imaging probe targeting αVβ3 integrin in glioblastoma xenografts. |
| Q86837102 | A novel PET tracer for targeted imaging of atherosclerosis |
| Q85553370 | A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients |
| Q33655854 | Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas |
| Q38014949 | Advances in malignant glioma drug discovery |
| Q48147806 | Binding of αvβ3 Integrin-Specific Radiotracers Is Modulated by Both Integrin Expression Level and Activation Status |
| Q35080057 | Cellular density effect on RGD ligand internalization in glioblastoma for MRI application. |
| Q38265614 | Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma |
| Q33417361 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial |
| Q37046781 | Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome |
| Q38032282 | Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies |
| Q39770397 | Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies |
| Q26771417 | Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3 |
| Q37815405 | Clinical applications in molecular imaging |
| Q38440214 | Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. |
| Q38691508 | Crossing the barrier: treatment of brain tumors using nanochain particles |
| Q33829590 | Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: An in vitro boron neutron capture therapy study |
| Q61797301 | Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis |
| Q27023823 | Emerging methods for disease monitoring in malignant gliomas |
| Q37157248 | Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma |
| Q34556242 | FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues |
| Q49158345 | Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of αvβ3 integrin expression |
| Q36244724 | Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence |
| Q94556014 | Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study |
| Q34203930 | Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours |
| Q58602364 | Imaging breast cancer using a dual-ligand nanochain particle |
| Q35999557 | Imaging key biomarkers of tumor angiogenesis |
| Q42602933 | Imaging of Integrin αvβ3 Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer 99mTc-IDA-D-[c(RGDfK)]2 |
| Q36230578 | Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas |
| Q34319898 | Impairment of the cell-to-matrix adhesion and cytotoxicity induced by the Mediterranean jellyfish Pelagia noctiluca venom and its fractions in cultured glioblastoma cells |
| Q31043472 | Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas |
| Q39200138 | Integrin control of the transforming growth factor-β pathway in glioblastoma. |
| Q42165286 | Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. |
| Q37236103 | Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics |
| Q38398188 | Longitudinal expression analysis of αv integrins in human gliomas reveals upregulation of integrin αvβ3 as a negative prognostic factor |
| Q89036547 | MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results |
| Q38810997 | Molecular Acoustic Angiography: A New Technique for High-resolution Superharmonic Ultrasound Molecular Imaging |
| Q37732704 | Molecular imaging and targeted therapies |
| Q33722980 | Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies |
| Q33961188 | Molecular imaging of gliomas with PET: opportunities and limitations |
| Q30474770 | Molecular ultrasound assessment of tumor angiogenesis |
| Q92644673 | Nanocarrier-based drug combination therapy for glioblastoma |
| Q26828849 | Nanoparticle-facilitated functional and molecular imaging for the early detection of cancer |
| Q34028690 | Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. |
| Q31115540 | Non-invasive metabolic imaging of brain tumours in the era of precision medicine |
| Q36625112 | Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles |
| Q37603124 | Nuclear imaging of molecular processes in cancer |
| Q47960971 | One-pot synthesis of nanochain particles for targeting brain tumors |
| Q42726009 | PET Imaging of Integrin αVβ3 Expression |
| Q55364912 | PET imaging of 68Ga-NODAGA-RGD, as compared with 18F-fluorodeoxyglucose, in experimental rodent models of engrafted glioblastoma. |
| Q33578187 | PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed |
| Q34677001 | PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide |
| Q38228356 | PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. |
| Q48934675 | PET-MR in patients with glioblastoma multiforme |
| Q33846924 | Peptides and peptide hormones for molecular imaging and disease diagnosis |
| Q48158155 | Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences |
| Q36777285 | Positron emission tomography tracers for imaging angiogenesis |
| Q55098453 | Preparation and evaluation of a 68Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate. |
| Q30390273 | RGD-Targeted Ultrasound Contrast Agent for Longitudinal Assessment of Hep-2 Tumor Angiogenesis In Vivo |
| Q38166986 | RGD-based PET tracers for imaging receptor integrin αv β3 expression |
| Q89529826 | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology |
| Q38000044 | Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. |
| Q39373913 | Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging |
| Q52722719 | Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression. |
| Q34572049 | Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging |
| Q42139438 | Targeted therapy for glioma using cyclic RGD-entrapped polyionic complex nanomicelles |
| Q27026331 | The development, past achievements, and future directions of brain PET |
| Q30797166 | The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. |
| Q35251878 | Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle |
| Q50553926 | [(18)F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma. |
| Q55465071 | [Status and advances of RGD molecular imaging in lung cancer]. |
| Q45287510 | [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins. |
| Q34785222 | alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment |
Search more.